by Dan Roberts June 19, 2011 Introduction Since 2006, I have done my best to condense the high points of the previous year’s macular degeneration research into a single report that is concise and understandable for the layperson. I do so, because I understand first hand how important it is to be aware of everything [Read More]
News
Encapsulated Cell Technology (ECT)–A New Drug Delivery System
by Dan Roberts Updated March 30, 2015 A means of delivering drugs into the retina on a time release basis is being developed and proven safe and effective. It is achieved by a method called Encapsulated Cell Technology (ECT), being tested by Neurotech SA with support from the National Eye Institute (NEI), Bethesda, Maryland. A [Read More]
Stargardt Disease
by Dan Roberts (Updated May 25, 2011) Stargardt disease (also known as fundus flavimaculatus and Stargardt macular dystrophy) is the most common form of inherited juvenile macular degeneration. Inherited as an autosomal recessive trait, it is a severe form of MD that begins in late childhood, leading to legal blindness. Stargardt disease is symptomatically similar [Read More]
Ten Things to Know About Multivitamins
by Ellen Troyer CEO & Chief Research Officer Biosyntrx Nutritional Technology May 13, 2011 It’s easy to become confused with so many multivitamins choices available. To help sort out the facts, here are ten things eye doctors and their patients should look for when recommending or selecting an ocular health/full-body multivitamin supplement. 1. Both eye [Read More]
Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration
The CATT Research Group April 2011 In 2005, clinical trials established the efficacy of ranibizumab (Lucentis, Genentech) for the treatment of neovascular age-related macular degeneration (AMD), the leading cause of legal blindness in the United States. While awaiting approval for ranibizumab from the Food and Drug Administration, ophthalmologists began treating neovascular AMD with off-label use [Read More]